Among the most profound results presented at the 2024 European Society for Medical Oncology (ESMO) Congress were the 10-year ...

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...

AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific (APAC) countries played to individual strengths to maximize AI’s applications in the health care sector. While ...

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...

Io Therapeutics Inc. has presented new preclinical data on their RARγ agonist IRX-5010 for the treatment of triple-negative ...

When every hour’s delay in treatment increases the risk of death 8%, dialing down time to diagnosis takes on acute urgency for clinicians and regulators. When the disease being treated kills 20% of ...

Gait instability and somnolence are the main hindbrain-related adverse effects associated with the inhibition of AMPA receptors (AMPARs). Transmembrane AMPAR regulatory proteins (TARPs) modulate AMPAR ...

The milestone is for the identification of candidates meeting the predefined lead compound criteria, and follows the initial milestone achieved in December 2023.

Kaken Pharmaceutical Co. Ltd. and Johnson & Johnson (J&J) have entered into a license agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and ...

Researchers from Arvinas Inc. reported the preclinical characterization of bavdegalutamide (ARV-110), an androgen receptor (AR)-directed proteolysis targeting chimera (PROTAC) designed to selectively ...

Revolution Medicines Inc. has synthesized macrocyclic compounds acting as GTPase KRAS, NRAS, HRAS and their mutant inhibitors reported to be useful for the treatment of cancer.